Caris Life Sciences publishes Q3 2026 financial results presentation
CAI•Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year, and GAAP net income of $15.3 million. Adjusted EBITDA was $44.4 million, its sixth consecutive positive quarter.
1. Quarterly results
Third-quarter clinical case volume rose 21% to approximately 61,500, while molecular profiling revenue increased 27% to $262.7 million. Nine-month revenue totaled $755.2 million, and cash and securities stood at $769.2 million. Caris Assure therapy response monitoring launched, and Caris Confirm minimal residual disease testing was scheduled for December 2026.
